Abstract
Disposition parameters of quinidine and three of its metabolites, 3-hydroxy quinidine, quinidine N-oxide, and quinidine 10,11-dihydrodiol, were determined in five normal healthy volunteers after prolonged intravenous infusion and multiple oral doses. The plasma concentrations of individual metabolites after 7 hr of constant quinidine infusion at a plasma quinidine level of 2.9±(SD) 0.3 mg/L were: 3-hydroxy quinidine, 0.32±0.06 mg/L; quinidine N-oxide, 0.28±0.03 mg/L; and quinidine 10,11-dihydrodiol, 0.13±0.04 mg/L. Plasma trough levels after 12 oral doses of quinidine sulfate every 4 hr averaged: quinidine, 2.89±0.50 mg/L; 3-hydroxy quinidine, 0.83±0.36 mg/L; quinidine N-oxide, 0.40±0.13 mg/L; and quinidine 10,11-dihydrodiol, 0.38±0.08 mg/L. Relatively higher plasma concentrations of 3-hydroxy quinidine metabolite after oral dosing probably reflect first-pass formation of this quinidine metabolite. A two-compartment model for quinidine and a one-compartment model for each of the metabolites described the plasma concentration-time curves after both i.v. infusion and multiple oral doses. Mean (±SD) disposition parameters for quinidine from individual fits, after i.v. infusion were as follows: V 1 ,0.37±0.09 L/kg; λ1,0.094±0.009 min −1; λ2, 0.0015±0.0002 min−1; EX2, 0.013±0.002 min−1;clearance (ClQ),3.86±0.83 ml/min/kg. Both plasma and urinary data were used to determine metabolic disposition parameters. Mean (±SD) values for the metabolites after i.v. quinidine infusion were as follows: 3-hydroxy quinidine: formation rate constant kmf,0.0012±0.0005 min −1,volume of distribution, Vm,0.99±0.47 L/kg; and elimination rate constant, kmu 0.0030±0.0002 min −1.Quinidine N-oxide: kmf,0.00012±0.00003 min −1; Vm,0.068±0.020 L/kg; and kmu,0.0063±0.0008 min −1.Quinidine 10,11-dihydrodiol: kmf,0.0003±0.0001 min −1; Vm,0.43±0.29 L/kg; and kmu,0.0059±0.0010 min −1.Oral absorption of quinidine was described by a zero order process with a bioavailability of 0.78. Concentration dependent renal elimination of 3-hydroxy quinidine was observed in two out of five subjects studied.
Similar content being viewed by others
References
C. T. Ueda, B. J. Williamson, and B. S. Dzinzio. Absolute quinidine bioavailability.Clin. Pharmacol. Ther. 20:260–265 (1976).
T. W. Guentert, N. H. G. Holford, P. E. Coates, R. A. Upton, and S. Riegelman. Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies.J. Pharmacokin. Biopharm. 7:315–330 (1979).
D. J. Greenblatt, H. J. Pfeifer, H. R. Ochs, D. S. Maclaughlin, T. W. Smith, and J. Koch-Weser. Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration.J. Pharmacol. Exp. Ther. 202:365–378 (1977).
D. E. Drayer, M. Hughes, B. Lorenzo, and M. M. Reidenberg. Prevalance of high (3S)-3-hydroxy quinidine/quinidine ratios in serum, and clearance of quinidine in cardiac patients with age.Clin. Pharmacol. Ther. 27:72–75 (1980).
N. H. G. Holford, P. E. Coates, T. W. Guentert, S. Riegelman, and L. B. Sheiner. The effect of quinidine and its metabolites on the electrocardiogram and systolic intervals.Br. J. Clin. Pharmacol. 11:187–195 (1981).
D. E. Drayer, D. T. Lowenthal, K. M. Restivo, A. Schwartz, C. E. Cook, and M. M. Reidenberg. Steady-state serum levels of quinidine and active quinidine metabolites in cardiac patients with varying degrees of renal function.Clin. Pharmacol. Ther. 24: 31–39 (1978).
A. Rakhit, M. Kunitani, N. H. G. Holford, and S. Riegelman. Improved liquid-chromatographic assay of quinidine and its metabolites in biological fluids.Clin. Chem. 28:1505–1509 (1982).
T. W. Guentert, J. J. Daly, and S. Riegelman. Isolation and identification of a new quinidine metabolite.Eur. J. Drug Metab. Pharmacokin. 7:31–38 (1982).
Y. Yanuka, S. Yosselson-Superstine, G. Geryes, and E. Superstein. Assignment and configuration to potassium permanganate oxidation products of quinidine.J. Pharm. Sci. 70:675–679 (1981).
L. Z. Benet. General treatment of linear mamillary models with elimination from any compartment as used in pharmacokinetics.J. Pharm. Sci. 61:536–541 (1972).
M. Gibaldi and D. Perrier.Pharmacokinetics, Mercel Dekker, New York, 1975, p. 101.
N. H. G. Holford,MKMODEL. In H. M. Perry and J. J. Wood (editors),Public Procedures Notebook. Bolt Beranek and Newman, Cambridge, Mass., 1981, pp. 8–51.
W. F. Raub, “PROPHET” system and resource sharing.Fed. Proc. 33:2390 (1976).
E. P. Hiatt. Plasma concentrations following the oral administration of a single dose of the principal alkaloids of cinchona bark,J. Pharmacol. Exp. Ther. 81:160–163 (1944).
Author information
Authors and Affiliations
Additional information
This work was supported by funds from the grants GM 26691 and GM 28072 from the National Institute of General Medical Sciences, NIH. A. Rakhit was the recipient of a Training Grant Traineeship from NIH. T. W. Guentert is grateful for support from the Swiss National Science Foundation.
Professor Sidney Riegelman. deceased April 4, 1981.
Rights and permissions
About this article
Cite this article
Rakhit, A., Holford, N.H.G., Guentert, T.W. et al. Pharmacokinetics of quinidine and three of its metabolites in man. Journal of Pharmacokinetics and Biopharmaceutics 12, 1–21 (1984). https://doi.org/10.1007/BF01063608
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01063608